Is a Claim Term’s Whole Greater Than the Sum of Its Parts?
February 6, 2024, 2:15 PM
Claim terms are usually given their ordinary meaning in light of the intrinsic evidence, but what if the ordinary meaning of two claim terms presents an obvious contradiction? That is the issue that the Federal Circuit will address when it hears oral argument in Maxell v. Amperex Tech., No. 23-1194 on February 9, 2024.
Maxell appeals a partial final judgment under rule 54(b) from the Western District of Texas, holding invalid as indefinite all claims of U.S. Patent No. 9,077,035. The District Court’s ruling is grounded in a plain reading of the disputed term. The term’s first part (“M1 represents at least one transition metal element selected from Co, Ni and Mn”) renders cobalt (“Co”) optional, whereas the second part (“wherein the content of Co in the transition metal M1 of the formulae (1) and (2) is from 30% by mole to 100% by mole”) requires cobalt. The Court agreed with Amperex that this obvious contradiction gives rise to a lack of reasonable certainty whether cobalt is optional or required.
Maxell argues that the District Court erred in declining to read the two parts of the term together, “which resulted in its failure to recognize the claim scope defined by [their] intersection[.]” When read in its entirety, Maxell argues, a Person of Ordinary Skill in the Art (POSA) would understand that the term requires that M1 must include cobalt. Amperex responds that Maxell’s allegedly inconsistent position demonstrates the term’s “insoluble ambiguity.” According to Amperex, Maxell unsuccessfully argued during claim construction that the first half of the term requires cobalt and the second part of the term merely confirms it. Maxell then shifted to treating the second part of the term as modifying the first part, such that while the first part does not require the presence of cobalt, the percentage clause does. Amperex also argues that in the same claim, Maxell used language requiring magnesium (“Mg”) in M2 (“M2 represents Mg and at least one metal element selected from the group consisting of Ti, Zr, Ge, Nb, Al and Sn”), indicating that Maxell understood how to claim that M1 requires Co and permits Ni and Mn, but chose not to do so.
Both parties cited Multilayer Stretch Cling Film Holdings v. Berry Plastics, where the Court held a dependent claim indefinite for including an element excluded by its independent claim. 831 F.3d 1350, 1362 (Fed. Cir. 2016). Amperex argued that Multilayer is “no different,” while Maxell argued it was inapposite because the terms here are not mutually exclusive. Amperex also points to Allen Eng’g v. Bartell Indus., where the Court refused to correct an obvious contradiction, stating that “[i]t is not our function to rewrite claims to preserve their validity.” 299 F.3d at 1349 (Fed. Cir. 2002). Courts have latitude to correct “minor obvious typographical and clerical errors.” Pavo Solutions v. Kingston Tech., 35 F.4th 1367, 1373 (Fed. Cir. 2022). But the error in Pavo was a single word (reciting “case” instead of “cover”) whereas Maxell would re-write an entire phrase. Further, unlike the patentee in Pavo, Maxell treated the issue as an ordinary claim construction dispute and did not ask the District Court to correct the claim. Id. at 1375 (distinguishing Chef America v. Lamb-Weston, 358 F.3d 1371 (Fed. Cir. 2004), in part because the patentee in that case did not seek correction). In light of those differences, it will be interesting to see what the Federal Circuit panel has to say during oral argument and whether it is inclined to uphold the District Court’s finding of indefiniteness.
Maxell argues that the District Court erred in declining to read the two parts of the term together, “which resulted in its failure to recognize the claim scope defined by [their] intersection[.]”

To subscribe to our publications, click here.
News & Insights
News & Insights
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
ABA 2026 Antitrust Global Seminar Series
Speaking Engagement
Antitrust
Axinn Attorneys Earn Top Honors in Best Lawyers 2027
News
Antitrust
DOJ's Antitrust Division Remains Interested in Your Private Litigation
Byline Articles
Antitrust
Axinn Advises Thermo Fisher Scientific on Completed $1.075 Billion Sale of Microbiology Business to Astorg
Deals & Cases
Antitrust